These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30896281)

  • 21. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice.
    Meijs WE; Haisma HJ; Klok RP; van Gog FB; Kievit E; Pinedo HM; Herscheid JD
    J Nucl Med; 1997 Jan; 38(1):112-8. PubMed ID: 8998164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
    Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
    J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
    [No Abstract]   [Full Text] [Related]  

  • 23. Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT.
    Walther M; Gebhardt P; Grosse-Gehling P; Würbach L; Irmler I; Preusche S; Khalid M; Opfermann T; Kamradt T; Steinbach J; Saluz HP
    Appl Radiat Isot; 2011 Jun; 69(6):852-7. PubMed ID: 21397511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
    Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
    J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties.
    Lövqvist A; Lundqvist H; Lubberink M; Tolmachev V; Carlsson J; Sundin A
    Med Phys; 1999 Feb; 26(2):249-58. PubMed ID: 10076983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative biodistribution analysis across four different
    Bensch F; Smeenk MM; van Es SC; de Jong JR; Schröder CP; Oosting SF; Lub-de Hooge MN; Menke-van der Houven van Oordt CW; Brouwers AH; Boellaard R; de Vries EGE
    Theranostics; 2018; 8(16):4295-4304. PubMed ID: 30214621
    [No Abstract]   [Full Text] [Related]  

  • 28. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
    Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
    J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
    J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso.
    Cutler PD; Schwarz SW; Anderson CJ; Connett JM; Welch MJ; Philpott GW; Siegel BA
    J Nucl Med; 1995 Dec; 36(12):2363-71. PubMed ID: 8523133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
    Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
    J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
    Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
    Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.
    Antonescu C; Bischof Delaloye A; Kosinski M; Monnin P; Schaffland AO; Ketterer N; Grannavel C; Kovacsovics T; Verdun FR; Buchegger F
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):943-51. PubMed ID: 15824926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.